Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking

Posted Nov 26 2010 10:43am

Insomnia, sleep apnea, restless leg syndrome, bruxism, narcolepsy and sleepwalking are all serious sleep disorders that possess negative—and sometimes fatal—health consequences. Often undiagnosed and thus not treated, sleep disorders can not only take a toll on personal health but can also adverse effects on personal relationships and reduce worker productivity. In examining the troubling increase in a variety of sleep disorders, this report will analyze the causes and available treatments for sleep disorder sufferers. This is a particularly interesting time in the evolution of the sleep disorders market because the blockbuster drugs that have dominated this space are coming off patent protection. There has been a strong push on the part of the major pharmaceutical companies to develop or acquire replacement sources of revenue. In order to put sleep disorders in a proper context, the study begins with an examination of key characteristics of the overall sleep disorders market. The types of disorders, causes of insomnias, parasomnias and their treatments are analyzed, with the additional review of treatments including pharmaceuticals, devices (continuous positive airway pressure or CPAP machines) and others (nutraceuticals, etc.). The report goes on to describe the primary product offerings of the major companies in this market space including major classes of prescription and over-the-counter (OTC) pharmaceuticals. Finally, a review of companies developing treatments for insomnia, sleep apnea, restless leg syndrome, bruxism, narcolepsy and sleepwalking are examined.


Table of Contents :

1. Overview 12
1.1 Statement of Report 12
1.2 About This Report 12
1.3 Scope of the Report 13
1.4 Methodology 13
1.5 Executive Summary 14
1.6 U.S. Sleep Market 17
1.6.1 Sleep Drugs Market in the U.S. 17
1.6.2 U.S. Sleep Apnea Devices Market 18
1.6.3 U.S. Market for Mattresses and Other Related Products 18
1.6.4 Sleep Laboratories in the U.S. 19
1.6.4.1 Locate Sleep Centers in the U.S. 21
1.7 Future of Sleep Drugs 22
1.7.1 Sleep Drugs for Jet Lag and Shift Work 22
1.7.2 Sleep Drugs for Age-related Sleep Issues 23
1.7.3 Sleep Drugs for Those Who Cannot Sleep Through the Night 24
1.7.4 Sleep Drugs for Restless Leg Syndrome 24
1.7.5 Sleep Drugs for Insomnia 25
1.7.6 Sleep Drugs for Sleep Apnea 25

2. Introduction to Sleep Disorders 26
2.1 Sleep Disorders Overview 26
2.1.1 Sleep Facts from the U.S. 27
2.1.2 Consequences of Sleep Disorder Problems 27
2.2 Physiology of Sleep 27
2.2.1 Sleep Stages 28
2.2.2 Neutral Control of Sleep 29
2.3 Current Understanding of Sleep Disorders 29
2.3.1 Hypersomnia 30
2.3.1.1 Causes of Hypersomnia 30
2.3.1.2 Demographics of Hypersomnia 30
2.3.1.3 Treatment for Hypersomnia 31
2.4 Obstructive Sleep Apnea (OSA) 33
2.4.1 Causes of Sleep Apnea 33
2.4.2 Symptoms of Sleep Apnea 34
2.4.3 Demographics of Sleep Apnea 34
2.4.4 Diagnosis of Sleep Apnea 34
2.4.5 Treatments 35
2.4.5.1 Positional Therapy 35
2.4.5.2 Behavioral Therapy—Weight Loss 36
2.4.5.3 Oral Appliances 36
2.4.5.4 Surgery for Sleep Apnea 37
2.4.5.5 Nasal Continuous Positive Airway Pressure (CPAP) Therapy 37
2.4.5.6 Medications for Sleep Apnea 37
2.4.6 The National Ambulatory Medical Care Survey on Sleep Apnea 38
2.4.6.1 Age and Sleep Apnea in Men 41
2.5 Narcolepsy 42
2.5.1 Demographics of Narcolepsy 42
2.5.2 Causes of Narcolepsy 43
2.5.3 Symptoms of Narcolepsy 43
2.5.4 Diagnosis of Narcolepsy 43
2.5.5 Treatment for Narcolepsy 43
2.6 Insomnia 44
2.6.1 Causes of Insomnia 46
2.6.2 Symptoms of Insomnia 46
2.6.3 Demographics of Insomnia 47
2.6.4 Diagnosis of Insomnia 48
2.6.5 Insomnia and Obesity 48
2.6.6 Treatments for Insomnia 50
2.6.6.1 Behavioral Treatment for Insomnia 50
2.6.6.2 Treating Insomnia with Medications 50
2.6.6.3 Alternative Remedies for Insomnia 51
2.6.7 Insomnia Market 51
2.6.8 National Sleep Foundations’ “Sleep In America Poll” 55
2.6.8.1 Benzodiazepines 56
2.6.8.2 The Short-term Gold Standard 56
2.6.8.3 Emerging Players 56
2.6.8.4 Insomnia Market Indicators 57
2.6.8.5 Newer Sedative Drugs for Insomnia in 2008 57
2.7 Restless Legs Syndrome 61
2.7.1 Demographics of RLS 62
2.7.2 Causes of RLS 62
2.7.3 Symptoms of RLS 63
2.7.4 Diagnosis of RLS 63
2.7.5 Treatments for RLS 64
2.7.5.1 Lifestyle Changes and RLS 64
2.7.5.2 Treating RLS with Pharmaceuticals 64
2.8 Circadian Rhythm Disorders 65
2.8.1 Causes of Circadian Rhythm Disorders 65
2.8.2 Symptoms 66
2.8.3 Demographics of Circadian Rhythm Disorders 66
2.8.4 Diagnosis of Circadian Rhythm Disorders 66
2.8.5 Treatments for Circadian Rhythm Disorders 67
2.9 Parasomnias 67
2.9.1 Nightmare Disorder 67
2.9.2 Sleep Terror Disorder 67
2.9.3 Sleep Walking Disorder 67
2.9.4 Demographics of Parasomnias 68
2.9.5 Causes and Symptoms of Parasomnias 68
2.9.6 Diagnosis 68
2.9.7 Treatment for Parasomnias 68

3. Drugs Used for Sleep Disorders 69
3.1 Estazolam 69
3.2 Flurazepam (Dalmane) 69
3.3 Temazepam 70
3.4 Triazolam 71
3.5 Zopiclone (Inovane) 71
3.6 Nonbenzodiazepine Hypnotics 72
3.6.1 Eszopiclone (Lunesta) 72
3.6.2 Zaleplon (Sonata) 73
3.6.3 Zolpidem (Ambien, Ambien CR) 74
3.7 Pineal Gland Hormones 76
3.7.1 Melatonin 76
3.7.2 Ramelteon (Rozerem) 76
3.8 Antihistamines 77
3.8.1 Benadryl (Diphenhydramine) 77
3.8.2 Doxylamine 77
3.9 Antidepressants 78
3.9.1 Amitriptyline (Elavil) 78
3.9.2 Nortriptyline (Pamelor) 79
3.9.3 Nefazodone (Serzone) 80
3.9.4 Trazodone (Desyrel) 80
3.9.5 Indiplon 81
3.9.6 Gaboxadol 81
3.9.7 Silenor 82
3.10 Other Substances 83
3.10.1 Lavender 83
3.10.2 Passion Flower 84
3.10.3 Ashwagandha 84
3.10.4 Catnip 86
3.10.5 Kava (Piper methysticum) 87
3.10.6 Valerian 89
3.11 Aromatherapy 90
3.12 Some OTC Sleep Gadgets in the Market 91
3.12.1 Dreamateâ„¢ 91
3.12.2 Anti-snoring Pillow 91
3.12.3 Nasal Dialators 92
3.12.4 Nasal Strips 92
3.12.5 Snore Stopper 92
3.12.6 SleepMate 93
3.12.7 Antisnor Therapeutic Ring 93
3.12.8 Ayurvedic Treatment for Insomnia 94
3.12.9 Yoga for Sleep Disorders 94
3.12.10 Meditation for Sleep Disorders 96
3.12.11 Hypnosis for Sleep Disorders 97
3.13 Homeopathic Treatment for Sleep Disorders 97
3.13.1 Belladonna 97
3.13.2 Nux vomica 98
3.13.3 Chamomilla 98
3.13.4 Gelsemium 99
3.13.5 Cannabis Indica 99

4. A Guide to Better Sleep 101
4.1 The Normally Required Sleep 101
4.2 Sleep and Driving 101
4.3 Tips to Avoid Drowsy Driving 101
4.4 Tips to Find whether One has Sleep Disorders 102
4.5 A Good Night’s Sleep 102

5. Sleep Laboratories 104

6. Profiles of Companies and Their Product Offering 107
6.1 Device Companies (CPAP and Other) 107
6.1.1 AEIOmed, Inc. and Product Offerings 107
6.1.2 Chad Therapeutics, Inc. and Product Offerings 108
6.1.3 Compumedics Ltd. and Product Offerings 113
6.1.4 Puritan Bennett (Covidien) and Product Offerings 122
6.1.5 ResMed Corporation and Product Offerings 135
6.1.6 Respironics, Inc. (Philips) 145
6.1.7 CleveMed and Product Offerings 153
6.1.8 SomnoMed Ltd. and Product Offerings 156
6.2 Pharmaceutical (Prescription and OTC) Companies 157
6.2.1 Acadia Pharmaceuticals, Inc. 157
6.2.1.1 Pimavanserin for the Treatment of Parkinson’s Disease Psychosis 158
6.2.1.2 Pimavanserin as a Co-therapy for Schizophrenia 158
6.2.1.3 ACP-104 for the Treatment of Schizophrenia 158
6.2.1.4 Pimavanserin for the Treatment of Sleep Maintenance Insomnia 158
6.2.1.5 Neuropathic Pain 158
6.2.1.6 Glaucoma 158
6.2.2 Actelion Ltd. 160
6.2.2.1 Actelion’s Tracleer® 164
6.2.2.2 Tracleer in Digital Ulcers 165
6.2.2.3 Actelion’s Ventavis® 165
6.2.2.4 Actelion’s Zavesca® 165
6.2.2.5 Actelion’s Focus on Sleep and Sleep Disorders 165
6.2.2.6 The Orexin System 165
6.2.2.7 Almorexant in Clinical Development 165
6.2.3 Arena Pharmaceuticals, Inc. 166
6.2.3.1 Arena’s R&D Programs 166
6.2.3.2 Arena Pharmaceuticals’ Development Pipeline 167
6.2.3.3 Locaserin Hydrochloride for Obesity 168
6.2.3.4 APD125 for Insopmnia 168
6.2.4 Cephalon, Inc. 171
6.2.5 Eli Lilly and Company 174
6.2.5.1 Eli Lilly’s Product Acquisitions, 2007 178
6.2.6 GlaxoSmithKline Plc 179
6.2.7 King Pharmaceuticals, Inc. and Product Offerings 188
6.2.7.1 King Pharmaceutical’s R&D 192
6.2.7.2 King Pharmaceutical’s Manufacturing 192
6.2.7.3 King Pharmaceutical’s Financial Highlights 192
6.2.8 Neurogen Corporation 192
6.2.8.1 Neurogen’s Insomnia Products 195
6.2.8.2 Positive Results in Phase IIb Studies in Chronic Insomnia 195
6.2.8.3 Positive Results in Phase IIb Studies with Adipiplon 195
6.2.8.4 Study 202—Primary Endpoint Sleep Maintenance 196
6.2.8.5 Study 203—Primary Endpoint Sleep Onset 196
6.2.8.6 Transient Insomnia 198
6.2.8.7 Study Results 198
6.2.8.8 Study Design 198
6.2.9 Neurocrine Biosciences, Inc. 199
6.2.9.1 Neurocrine’s Pipeline—GnRH Antagonists 200
6.2.9.2 Corticotropin Releasing Factor (CRF1) Receptor Antagonists 201
6.2.9.3 Urocortin 2 for Congestive Heart Failure (CHF) 201
6.2.9.4 Neurocrine’s Research Programs 201
6.2.9.5 Indiplon 201
6.2.10 Pfizer, Inc. and Product Offerings 202
6.2.10.1 Lipitor 204
6.2.10.2 Norvasc 204
6.2.10.3 Celebrex 204
6.2.10.4 Lyrica 204
6.2.10.5 Viagra

For more information, please visit : http://www.aarkstore.com/reports/Sleep-Disorders-Insomnia-Sleep-Apnea-Restless-L

Contact :Sanaa

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Post a comment
Write a comment:

Related Searches